What it is

CJC-1295 is a long-acting analog of growth hormone–releasing hormone (GHRH). Some versions were designed with a “drug affinity complex” (DAC) concept to extend half-life by binding to circulating proteins, enabling prolonged stimulation of endogenous growth hormone (GH) secretion.

CJC-1295 is not FDA-approved. It is also discussed in anti-doping contexts.

Why people use it

It is used in some settings with the intent to increase endogenous GH and IGF-1. Non-medical use often targets body composition, recovery, or “anti-aging” claims, which are not established indications.

History and origin

Long-acting GHRH analog development reflects a broader endocrinology goal: stimulate physiologic GH pulsatility through the pituitary rather than administer exogenous GH. CJC-1295 appears in the literature as an engineered long-acting GHRH analog studied in healthy adults.

How it works

CJC-1295 activates the GHRH receptor in the pituitary, increasing GH secretion and downstream hepatic IGF-1 production. The DAC approach prolongs exposure, so the biologic effect can persist longer than native GHRH(1–44) or shorter fragments.

A key mechanistic nuance is that the endocrine system remains regulated by somatostatin tone, sleep, nutrition, and feedback through IGF-1, so outcomes may not mirror those of direct GH administration.

Evidence landscape

Human studies demonstrate prolonged stimulation of GH and IGF-1 in healthy adults. Evidence for meaningful clinical benefit in aging, injury recovery, or athletic performance is limited, and risks of supraphysiologic IGF-1 and unintended endocrine effects remain relevant.

Safety reality

Potential risks include edema, arthralgias, insulin resistance, and endocrine dysregulation, conceptually similar to other GH/IGF-1–elevating strategies. Product quality is a major issue outside regulated manufacturing. Use is also relevant to sport anti-doping policies.

References

Prolonged stimulation of GH and IGF-I secretion by CJC-1295 in healthy adults (2006). https://pubmed.ncbi.nlm.nih.gov/16352683/

Pulsatile GH secretion persists during continuous stimulation by CJC-1295 (2006). https://pubmed.ncbi.nlm.nih.gov/17018654/

Evaluate CJC-1295 in HIV patients with visceral obesity (ClinicalTrials.gov). https://clinicaltrials.gov/study/NCT00267527